Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.48 |
| ▸ | ICMT | O60725 | 3/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | EDNRB | P24530 | 2/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092341 | 0.93 | PPARG (0.54) | PPARGKMT2APLA2G2AF2RL3ICMT | |
| SCHEMBL6857727 | 0.91 | PPARG (0.72) | PPARGKMT2AF2RL3MAPK8 | |
| SCHEMBL6093344 | 0.91 | PPARG (0.65) | PPARGPLA2G2AF2RL3ICMTSERPINE1 | |
| SCHEMBL6091159 | 0.89 | PPARG (0.65) | PPARGF2RL3ICMTSERPINE1EDNRB | |
| SCHEMBL6089564 | 0.88 | PPARG (0.54) | PPARGPLA2G2AF2RL3ICMT | |
| SCHEMBL6092537 | 0.85 | PPARG (0.59) | PPARGF2RL3SERPINE1EDNRBEDNRA | |
| SCHEMBL6090091 | 0.85 | PPARG (0.57) | PPARGF2RL3ICMTSERPINE1EDNRB | |
| SCHEMBL5772496 | 0.84 | PPARG (0.57) | PPARGPLA2G2AF2RL3ICMTSERPINE1 | |
| SCHEMBL6093520 | 0.83 | PPARG (0.58) | PPARGF2RL3ICMTSERPINE1EDNRB | |
| SCHEMBL6858382 | 0.82 | PPARG (0.76) | PPARGKMT2AF2RL3SERPINE1EDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | IDO1, PTGS1, IDO2 | PPARG 481/4885KMT2A 3542/4885PLA2G2A 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.